Related Experiment Videos
Excellent results with clorazepate in recalcitrant childhood epilepsies
Insights
Clorazepate combined with sodium valproate effectively reduced severe generalized seizures in children. This combination therapy, particularly for refractory epilepsy, showed significant seizure frequency reduction with minimal side effects.
Area of Science:
- Pediatric Neurology
- Clinical Pharmacology
Background:
- Generalized seizures in children can be incapacitating and difficult to manage.
- Existing treatments may have limitations in efficacy or tolerability.
Purpose of the Study:
- To evaluate the efficacy and safety of clorazepate as an adjunct therapy for severe generalized seizures in children.
- To assess the impact of adding clorazepate to sodium valproate treatment.
Main Methods:
- Eleven children (3-17 years) with severe generalized seizures were treated.
- Initial treatment involved sodium valproate; clorazepate was added if seizures persisted or alone in 3 cases.
- Seizure frequency, valproate levels, and side effects were monitored.
Main Results:
- Combination therapy with sodium valproate and clorazepate led to a marked decrease in seizure frequency within 24-72 hours.
- Three children receiving clorazepate alone had inadequate seizure control despite therapeutic valproate levels.
- Side effects were minimal, with one patient experiencing a nocturnal tonic-clonic seizure.
Conclusions:
- Clorazepate appears to be a useful adjunctive treatment for children with severe generalized seizures refractory to other therapies.
- The combination of sodium valproate and clorazepate demonstrated significant efficacy in reducing seizure burden.
- Further research may explore optimal dosing and long-term outcomes of this combination therapy.
Abstract:
Eleven children with severe incapacitating generalized seizures were treated with sodium valproate and clorazepate and responded with a marked decrease in seizure frequency. Three children received clorazepate alone, either because of valproate toxicity or because of parental concern over side effects. These children, 5 males and 6 females, ranged in age from 3 to 17 years. They manifested normal to severely retarded intelligence. Although valproate levels were in the therapeutic range, seizure control was inadequate. When clorazepate was added to valproate therapy a marked reduction in seizure frequency occurred within 24 hours and became optimal within 48 to 72 hours. Side effects were minimal with the exception of a nocturnal generalized tonic-clonic seizure in a single patient. Three children were withdrawn from therapy after a year because of recurrent seizures. One patient was restarted on therapy after 6 months and seizure control improved. Clorazepate may be a useful adjunct in the treatment of primary generalized seizures in children.